TIBET RHODIOLA PHARMACEUTICAL HOLDING CO. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.15 CNY | +1.16% |
|
-3.02% | +4.29% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 54% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- With a P/E ratio at 12.32 for the current year and 10.28 for next year, earnings multiples are highly attractive compared with competitors.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +4.29% | 1.72B | - | ||
| +29.56% | 682B | C+ | ||
| +30.35% | 586B | B | ||
| -3.79% | 364B | C+ | ||
| +17.61% | 327B | B- | ||
| +3.30% | 285B | C+ | ||
| +15.53% | 240B | B+ | ||
| +10.16% | 209B | B- | ||
| -8.14% | 203B | A+ | ||
| +7.37% | 165B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600211 Stock
- Ratings Tibet Rhodiola Pharmaceutical Holding Co.
